Healthcare >> Analyst Interviews >> September 30, 2020
David Nierengarten, Ph.D., is Managing Director, Equity Research at Wedbush Securities. He has been a senior analyst covering small-mid cap biotech stocks with a heavy focus on oncology, rare disease and gene therapy. His prior experience in venture capital and operations at a private biotechnology company helps him succeed in analyzing both science and business models. In addition, Dr. Nierengarten has results in predicting Dendreon’s looming bankruptcy, and several M&A events involving NPS Pharmaceuticals and Anacor. Dr. Nierengarten received his B.S. in Biochemistry from the University of Wisconsin-Madison and Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.
Profile
Word count: 3,444
TWST: Could you tell me about the company?
Dr. Nierengarten: Sure. We're a midsize investment bank, headquartered in Los Angeles. I'm
